Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial

Targeted anti-inflammatory systemic therapy for restenosis: The Biorest Liposomal Alendronate with Stenting sTudy (BLAST)—a double blind, randomized clinical trial

Background Activation of systemic innate immunity is critical in the chain of events leading to restenosis. LABR-312 is a novel compound that transiently modulates circulating monocytes, reducing accumulation of these cells at vascular injury sites and around stent struts. The purpose of the study...

Full description

Bibliographic Details
Main Authors: Banai, Shmuel, Finkelstein, Ariel, Almagor, Yaron, Assali, Abid, Hasin, Yonathan, Rosenschein, Uri, Apruzzese, Patricia, Lansky, Alexandra J., Kume, Teruyoshi, Edelman, Elazer R.
Other Authors: Harvard University--MIT Division of Health Sciences and Technology
Format: Article
Language:en_US
Published: Elsevier 2016
Online Access:http://hdl.handle.net/1721.1/102570
https://orcid.org/0000-0002-7832-7156

Internet

http://hdl.handle.net/1721.1/102570
https://orcid.org/0000-0002-7832-7156

Similar Items